Image source: Exelixis.
What: Exelixis (NASDAQ: EXEL) is up 10% as we approach the closing bell today after the biotech and its partners presented data at the American Society of Clinical Oncology (ASCO) meeting over the weekend.
So what: The biotech had multiple presentations at ASCO, and it seems to be a combination of those data with perhaps some relief that nothing bad cropped up that has investors hitting the buy button.